We are live on ! Find out more
HMC

Harvard Management Company Portfolio holdings

AUM $1.82B
1-Year Est. Return 26.23%
This Fund
S&P 500
This Quarter Est. Return
+23.18%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$1.02B
AUM Growth
+$67.1M
Cap. Flow
-$123M
Cap. Flow %
-12.11%
Top 10 Hldgs %
94.35%
Holding
48
New
–
Increased
5
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
TSM icon
TSMC
TSM
+$8.85M
2
AMD icon
Advanced Micro Devices
AMD
+$5.75M
3
PCTTW
PureCycle Technologies Inc Warrant
PCTTW
+$5.57M
4
ASML icon
ASML
ASML
+$4.99M
5
PACB icon
Pacific Biosciences
PACB
+$49.1K

Top Sells

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$31M
2
PCT icon
PureCycle Technologies
PCT
+$12.9M
3
AMAT icon
Applied Materials
AMAT
+$10.9M
4
ADI icon
Analog Devices
ADI
+$10.8M
5
QRVO icon
Qorvo
QRVO
+$10.6M

Sector Composition

Rank Sector Weight
1 Communication Services 60.33%
2 Consumer Discretionary 18.08%
3 Technology 12.76%
4 Healthcare 5.21%
5 Industrials 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLO icon
26
Xilio Therapeutics
XLO
$59.5M
$1.09M 0.11%
29,719
– –
KITT icon
27
Nauticus Robotics
KITT
$6.67M
$1.06M 0.1%
193
– –
PRAX icon
28
Praxis Precision Medicines
PRAX
$8.52B
$797K 0.08%
46,174
-5,727
-11% -$87.7K
PRDS
29
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$724K 0.07%
400,000
– –
MCRB icon
30
Seres Therapeutics
MCRB
$48.7M
$632K 0.06%
6,592
– –
SRZN icon
31
Surrozen
SRZN
$253M
$455K 0.04%
55,123
– –
IRON icon
32
Disc Medicine
IRON
$2.93B
$375K 0.04%
8,452
-16,548
-66% -$587K
DNTH icon
33
Dianthus Therapeutics
DNTH
$5.8B
$252K 0.02%
20,788
– –
ABCL icon
34
AbCellera Biologics
ABCL
$1.78B
– –
-4,105,095
Closed -$31M
ADI icon
35
Analog Devices
ADI
$176B
– –
-54,568
Closed -$10.8M
AFRM icon
36
Affirm
AFRM
$25.3B
– –
-173,560
Closed -$1.96M
AMAT icon
37
Applied Materials
AMAT
$411B
– –
-88,443
Closed -$10.9M
DYN icon
38
Dyne Therapeutics
DYN
$4.71B
– –
-107,252
Closed -$1.24M
INTC icon
39
Intel
INTC
$459B
– –
-207,752
Closed -$6.79M
LOCO icon
40
El Pollo Loco
LOCO
$504M
– –
-45,188
Closed -$433K
LRCX icon
41
Lam Research
LRCX
$369B
– –
-191,310
Closed -$10.1M
MU icon
42
Micron Technology
MU
$937B
– –
-107,522
Closed -$6.49M
PATH icon
43
UiPath
PATH
$6.76B
– –
-69,073
Closed -$1.21M
PLRX icon
44
Pliant Therapeutics
PLRX
$64.4M
– –
-281,189
Closed -$7.48M
QRVO icon
45
Qorvo
QRVO
$7.89B
– –
-104,669
Closed -$10.6M
RLAY icon
46
Relay Therapeutics
RLAY
$4.09B
– –
-541,124
Closed -$8.91M
RVMD icon
47
Revolution Medicines
RVMD
$38.8B
– –
-315,550
Closed -$6.83M
MEKA
48
DELISTED
MELI Kaszek Pioneer Corp Class A Ordinary Shares
MEKA
– –
-1,000,000
Closed -$10.2M
1
2

Similar funds

DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $1.82B AUM 19.69% 1-Year Est. Return
MCC
Money Concepts Capital Palm Beach Gardens, Florida $1.81B AUM 21.93% 1-Year Est. Return
SI
Standard Investments New York $1.83B AUM 4.12% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $1.8B AUM 7.28% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
KAM
Kensington Asset Management Austin, Texas $1.84B AUM 13.95% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return

Harvard Management Company's Q2 2023 Portfolio in Review

As of Q2 2023, Harvard Management Company held 48 positions worth $1.02B, up 7% from $952M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Harvard Management Company withdrew a net $123M in Q2 2023, closing 15 positions and reducing 8 holdings. Its most notable exit was AbCellera Biologics, an estimated $31M position sold in full.

By sector, the portfolio is most concentrated in Communication Services at 60% of assets, up from 52% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Harvard Management Company added an estimated $8.85M to TSMC.

  • Harvard Management Company added most to TSMC in Q2 2023, an estimated $8.85M increase.
  • Harvard Management Company's biggest Q2 2023 reduction was PureCycle Technologies, cutting an estimated $12.9M.
  • Harvard Management Company fully exited AbCellera Biologics in Q2 2023, selling an estimated $31M.
  • Harvard Management Company's ten largest holdings make up 94% of its $1.02B portfolio in Q2 2023.
  • Harvard Management Company opened 0 new positions and closed 15 in Q2 2023.
  • Harvard Management Company's portfolio value rose 7% quarter-over-quarter to $1.02B.

Based on Harvard Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.